Acadia Pharmaceuticals ACAD EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Acadia Pharmaceuticals’s reported figures.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's EBITDA?
- Acadia Pharmaceuticals (ACAD) reported EBITDA of -$1.62M in Q1 2026.
- How has Acadia Pharmaceuticals's EBITDA changed year-over-year?
- Acadia Pharmaceuticals's EBITDA decreased by 107.3% year-over-year, from $22.24M to -$1.62M.
- What is the long-term trend for Acadia Pharmaceuticals's EBITDA?
- Over 3 years (2021 to 2025), Acadia Pharmaceuticals's EBITDA has grown at a -11.3% compound annual growth rate (CAGR), from -$167.03M to $116.57M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.